Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

R. N. Davidson; L. Di Martino; L. Gradoni; R. Giacchino; G. B. Gaeta; R. Pempinello; S. Scotti; A. Cascio; E. Castagnola; A. Maisto; M. Gramiccia; D. Di Caprio; R. J. Wilkinson; A. D M Bryceson

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

R. N. Davidson, L. Di Martino, L. Gradoni, R. Giacchino, G. B. Gaeta, R. Pempinello, S. Scotti, A. Cascio, E. Castagnola, A. Maisto, M. Gramiccia, D. Di Caprio, R. J. Wilkinson, A. D M Bryceson

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12 mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infantum, we recommend a total dose of AmBisome of ≤ 20 mg/kg, given in ≤ 5 doses of 3-4 mg/kg over ≤ 10 days.

Original language	English
Pages (from-to)	938-943
Number of pages	6
Journal	Clinical Infectious Diseases
Volume	22
Issue number	6
Publication status	Published - 1996

ASJC Scopus subject areas

Immunology

Cite this

@article{79ea0d21daa84bf993c1a01b17c02abc,

title = "Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)",

abstract = "We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12 mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infantum, we recommend a total dose of AmBisome of ≤ 20 mg/kg, given in ≤ 5 doses of 3-4 mg/kg over ≤ 10 days.",

author = "Davidson, {R. N.} and {Di Martino}, L. and L. Gradoni and R. Giacchino and Gaeta, {G. B.} and R. Pempinello and S. Scotti and A. Cascio and E. Castagnola and A. Maisto and M. Gramiccia and {Di Caprio}, D. and Wilkinson, {R. J.} and Bryceson, {A. D M}",

year = "1996",

language = "English",

volume = "22",

pages = "938--943",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "NLM (Medline)",

number = "6",

}

TY - JOUR

T1 - Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

AU - Davidson, R. N.

AU - Di Martino, L.

AU - Gradoni, L.

AU - Giacchino, R.

AU - Gaeta, G. B.

AU - Pempinello, R.

AU - Scotti, S.

AU - Cascio, A.

AU - Castagnola, E.

AU - Maisto, A.

AU - Gramiccia, M.

AU - Di Caprio, D.

AU - Wilkinson, R. J.

AU - Bryceson, A. D M

PY - 1996

Y1 - 1996

N2 - We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12 mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infantum, we recommend a total dose of AmBisome of ≤ 20 mg/kg, given in ≤ 5 doses of 3-4 mg/kg over ≤ 10 days.

AB - We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12 mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infantum, we recommend a total dose of AmBisome of ≤ 20 mg/kg, given in ≤ 5 doses of 3-4 mg/kg over ≤ 10 days.

UR - http://www.scopus.com/inward/record.url?scp=0029743517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029743517&partnerID=8YFLogxK

M3 - Article

C2 - 8783690

AN - SCOPUS:0029743517

SN - 1058-4838

VL - 22

SP - 938

EP - 943

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this